CliffBio
small molecule

BEPOTASTINE BESILATE

BEPOTASTINE BESILATE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBEPOTASTINE BESILATE
Active ingredientBEPOTASTINE BESILATE
Strength1.5%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.